Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr307 Inhibitors

Olr307 inhibitors represent a unique and specialized class of chemical compounds characterized by their ability to selectively interact with the Olr307 receptor, which is part of the larger olfactory receptor family. These receptors, primarily found in the olfactory epithelium, are G-protein-coupled receptors (GPCRs) that play a pivotal role in the detection of volatile chemical compounds. Olr307 inhibitors are particularly interesting due to their ability to modulate the signal transduction pathways associated with this receptor, often leading to the suppression or alteration of olfactory signaling. These inhibitors can provide insights into the structural and functional dynamics of the Olr307 receptor, contributing to a deeper understanding of the molecular mechanisms underlying olfactory perception.

The chemical structures of Olr307 inhibitors typically include functional groups that allow for specific interactions with the binding sites of the Olr307 receptor. These interactions are usually characterized by hydrogen bonding, van der Waals forces, and sometimes covalent modifications that lead to the inhibition of the receptor's activity. The design and synthesis of these inhibitors often involve complex organic chemistry techniques, including the use of stereoselective synthesis to achieve the desired enantiomeric purity, which is crucial for the selective inhibition of the receptor. Moreover, Olr307 inhibitors are frequently studied in the context of their ability to serve as molecular probes, allowing researchers to map the receptor's binding domains and understand the conformational changes that occur upon ligand binding. These inhibitors thus provide valuable tools for dissecting the molecular architecture of olfactory receptors and elucidating the broader principles of GPCR function.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Ulixertinib

869886-67-9sc-507296
10 mg
$176.00
(0)

ERK1/2 inhibitor, affects MAPK signaling, potentially influencing Olr307's signaling cascade.

Zanubrutinib

1691249-45-2sc-507434
5 mg
$360.00
(0)

Bruton's tyrosine kinase inhibitor, can impact cell signaling pathways relevant to Olr307.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$114.00
$166.00
$947.00
19
(1)

MEK inhibitor, affects the MAPK/ERK pathway, potentially influencing Olr307's function.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$251.00
$500.00
$547.00
16
(1)

JAK inhibitor, can alter cytokine signaling, potentially affecting Olr307's activity.

Selumetinib

606143-52-6sc-364613
sc-364613A
sc-364613B
sc-364613C
sc-364613D
5 mg
10 mg
100 mg
500 mg
1 g
$29.00
$82.00
$420.00
$1897.00
$3021.00
5
(1)

MEK inhibitor, might influence MAPK/ERK pathway related to Olr307's function.

BAY 80-6946

1032568-63-0sc-503264
5 mg
$562.00
(0)

PI3K inhibitor, can disrupt pathways potentially associated with Olr307.

Osimertinib

1421373-65-0sc-507355
5 mg
$86.00
(0)

EGFR inhibitor, potentially disrupts pathways Olr307 might be involved in.

ABT-199

1257044-40-8sc-472284
sc-472284A
sc-472284B
sc-472284C
sc-472284D
1 mg
5 mg
10 mg
100 mg
3 g
$118.00
$337.00
$520.00
$832.00
$1632.00
10
(0)

BCL-2 inhibitor, can modulate apoptosis pathways potentially linked to Olr307 function.

Baricitinib

1187594-09-7sc-364730
sc-364730A
5 mg
25 mg
$200.00
$664.00
(1)

JAK inhibitor, might influence cytokine signaling and pathways related to Olr307.